MTOR and breast carcinoma: Repression of ferroptosis could promote tumor progression, using anti-tumor drugs such as PI3K-AKT-mTOR pathway inhibitors (GDC-0941, MK-2206) which could promote sensitivity to ferroptosis in breast cancer cells (48).